logo-loader
RNS
IP Group PLC

IP Group PLC - Istesso starts trial of leramistat in sarcopenia

RNS Number : 3860I
IP Group PLC
16 June 2026
 

FOR RELEASE ON

16 June 2026

 

Portfolio company Istesso starts Phase 2 clinical trial of leramistat in sarcopenia

IP Group plc (LSE: IPO), which invests in breakthrough science and technology companies with the potential to create a better future for all, notes that portfolio company Istesso has commenced dosing in IST-03, a Phase 2 clinical trial of its lead candidate, leramistat, in patients with sarcopenia caused by rheumatoid arthritis.

The randomised, double-blind, placebo-controlled study is evaluating the effects of leramistat on muscle quality, repair and function. Sarcopenia (muscle loss) is a significant and growing unmet need across ageing populations and multiple chronic diseases, for which no specific pharmacological therapies are available.

The clinical study builds on prior rheumatoid arthritis data showing leramistat improved disability and fatigue alongside reductions in markers of muscle loss. This is supported by preclinical findings showing restoration of muscle quality in disease models and recovery of muscle mass, quality and function in aged animals to levels greater than those seen in baseline younger animals.

The aim of the study is to show that it is possible to augment the human capacity to repair. If successful, this would have implications for the treatment of chronic degenerative and age-related diseases.

Leramistat is the lead candidate from Istesso's novel class of Mitochondrial Complex I Modulators (MCMs), which have demonstrated the ability to induce adaptive tissue repair and regeneration across multiple tissues, including muscle, bone, gut and lung.

Enrolment is currently underway at Newcastle University and Newcastle Hospitals, in conjunction with the National Institute for Health and Care Research (NIHR) whose specialist facilities and biopsy expertise include advanced imaging and analysis techniques that are ideally suited to delivering this innovative trial.

Greg Smith, Chief Executive of IP Group, said: "This marks an important inflection point for Istesso as it moves into Phase 2 evaluation of a genuinely novel approach to regenerative medicine. The programme is supported by a consistent body of clinical and preclinical data, and we believe the potential to influence underlying tissue repair represents a differentiated and scalable opportunity. Success here would be an important validation of the approach and open up multiple opportunities across large areas of unmet need."

IP Group has an undiluted holding of 56.5% in Istesso.

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Liz Vaughan-Adams, Communications

+44 (0) 20 7444 0062/+44 (0) 7967 312125

Portland

Lewis Bendall-Craft

+44 (0) 7931 973950

 

Notes for editors

 

About IP Group

 

IP Group accelerates the impact of science for a better future. As the most active UK based, early stage science and technology investor, we develop and support some of the world's most exciting businesses in healthtech, deeptech and cleantech. Including through Parkwalk, the UK's largest growth EIS fund manager, we back world-changing innovation emerging in leading universities and research institutions. Our specialist investment team combines sector expertise with an international approach. Together we have a strong track record of success, having backed high-profile companies including Oxford Nanopore Technologies plc, Hinge Health, Featurespace, First Light Fusion, Hysata, and Oxa. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com.

 

About Istesso

Istesso is developing pioneering oral regenerative medicines that enhance the body's ability to repair, redefine treatment expectations and make a lasting impact on peoples' lives. We stand apart, disrupting conventional thinking and seeking robust science-led treatment solutions to enable people to live free from chronic disease. Scientists at heart, with almost 1,000 years of drug discovery expertise, we are the only company to understand and exploit the body's natural biology of repair. To learn more please visit us at: www.istesso.co.uk  

ENDS

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFAMTTMTTBTMF
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Metals One, Arrow Exploration, IXICO, Ilika, IP Group - Small Cap Snapshot

Metals One PLC (AIM:MET1, FRA:HT7, OTCQB:MTOPF) has agreed to buy full ownership of South African gold and power business Lions Bay Resources for £6.5 million in shares. The key asset is the Barbrook Gold Mine, and the company is targeting first gold concentrate within six months of completion,...

4 weeks ago

4 min read